Shilpa Medica Limited
UkraineAll drugs from this manufacturer
-
The drug is intended for the treatment of advanced renal cell carcinoma in cases where a previous course of systemic therapy has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage axitinib 1 mg ATC: L01XE17
-
The drug is prescribed for the treatment of advanced renal cell carcinoma if a previous course of systemic therapy has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage axitinib 5 mg ATC: L01XE17
-
The drug is prescribed for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), adjuvant therapy for RCC, as well as progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules, hard gelatin
Active substance Dosage sunitinib 25 mg ATC: L01EX01
-
The drug is prescribed for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), adjuvant therapy for RCC, as well as progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules, hard gelatin
Active substance Dosage sunitinib 37.5 mg ATC: L01EX01
-
The drug is prescribed for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), adjuvant therapy for RCC, as well as progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules, hard gelatin
Active substance Dosage sunitinib 50 mg ATC: L01EX01
-
The drug is prescribed for the treatment of gastrointestinal stromal tumor (GIST), progressive renal cell carcinoma (RCC), adjuvant therapy for RCC, as well as progressive neuroendocrine tumors of the pancreas.
Dosage form: capsules, hard gelatin
Active substance Dosage sunitinib 12.5 mg ATC: L01EX01